Head-to-head evidence
Insulin Efsitora Alfa vs insulin glulisine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin Efsitora Alfa
Developed by Eli Lilly
NCT05275400 · Phase 3 · completed
The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.
insulin glulisine · Apidra
Marketed by Sanofi
NCT00290927 · Phase 3 · completed
The trial randomized 390 participants but was not blinded; the registry describes comparisons with oral diabetes therapy. Its primary efficacy endpoint was change in HbA1c, a surrogate measure, and because no results are posted, it is not possible to determine whether the primary comparison was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Efsitora Alfa's landscape · insulin glulisine's landscape